These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 20642247)

  • 1. Long-term tolerability and effectiveness of oxymorphone extended release in patients with cancer.
    Slatkin NE; Rhiner MI; Gould EM; Ma T; Ahdieh H
    J Opioid Manag; 2010; 6(3):181-91. PubMed ID: 20642247
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oxymorphone extended release for the treatment of chronic low back pain: a retrospective pooled analysis of enriched-enrollment clinical trial data stratified according to age, sex, and prior opioid use.
    Peniston JH; Gould E
    Clin Ther; 2009 Feb; 31(2):347-59. PubMed ID: 19302907
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A 2-week, multicenter, randomized, double-blind, placebo-controlled, dose-ranging, phase III trial comparing the efficacy of oxymorphone extended release and placebo in adults with pain associated with osteoarthritis of the hip or knee.
    Kivitz A; Ma C; Ahdieh H; Galer BS
    Clin Ther; 2006 Mar; 28(3):352-64. PubMed ID: 16750450
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A 12-week, randomized, placebo-controlled trial assessing the safety and efficacy of oxymorphone extended release for opioid-naive patients with chronic low back pain.
    Katz N; Rauck R; Ahdieh H; Ma T; Gerritsen van der Hoop R; Kerwin R; Podolsky G
    Curr Med Res Opin; 2007 Jan; 23(1):117-28. PubMed ID: 17257473
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety, tolerability, and effectiveness of oxymorphone extended release for moderate to severe osteoarthritis pain: a one-year study.
    McIlwain H; Ahdieh H
    Am J Ther; 2005; 12(2):106-12. PubMed ID: 15767827
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Titration with oxymorphone extended release to achieve effective long-term pain relief and improve tolerability in opioid-naive patients with moderate to severe pain.
    Rauck R; Ma T; Kerwin R; Ahdieh H
    Pain Med; 2008 Oct; 9(7):777-85. PubMed ID: 18950436
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Establishing the dosage equivalency of oxymorphone extended release and oxycodone controlled release in patients with cancer pain: a randomized controlled study.
    Gabrail NY; Dvergsten C; Ahdieh H
    Curr Med Res Opin; 2004 Jun; 20(6):911-8. PubMed ID: 15200750
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tolerability of concomitant use of selective serotonin reuptake inhibitors or serotonin-norepinephrine reuptake inhibitors and oxymorphone extended release.
    Peniston JH; Hu X; Potts SL; Wieman MS; Turk DC
    Postgrad Med; 2012 Mar; 124(2):114-22. PubMed ID: 22437221
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and tolerability of oxymorphone immediate release for acute postoperative pain after abdominal surgery: a randomized, double-blind, active- and placebo-controlled, parallel-group trial.
    Aqua K; Gimbel JS; Singla N; Ma T; Ahdieh H; Kerwin R
    Clin Ther; 2007 Jun; 29(6):1000-12. PubMed ID: 17692717
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness and safety of oral extended-release oxymorphone for the treatment of cancer pain: a pilot study.
    Sloan P; Slatkin N; Ahdieh H
    Support Care Cancer; 2005 Jan; 13(1):57-65. PubMed ID: 15538638
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of OPANA ER (oxymorphone extended release) for relief of moderate to severe chronic low back pain in opioid-experienced patients: a 12-week, randomized, double-blind, placebo-controlled study.
    Hale ME; Ahdieh H; Ma T; Rauck R;
    J Pain; 2007 Feb; 8(2):175-84. PubMed ID: 17145204
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Feasibility study of rapid opioid rotation and titration.
    Korkmazsky M; Ghandehari J; Sanchez A; Lin HM; Pappagallo M
    Pain Physician; 2011; 14(1):71-82. PubMed ID: 21267044
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Factors affecting acceptability of titrated oxymorphone extended release in chronic low back pain - an individual patient analysis.
    Peniston JH; Xiang Q; Gould EM
    Curr Med Res Opin; 2010 Aug; 26(8):1861-71. PubMed ID: 20521870
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of oxymorphone extended release in postsurgical pain: a randomized clinical trial in knee arthroplasty.
    Ahdieh H; Ma T; Babul N; Lee D
    J Clin Pharmacol; 2004 Jul; 44(7):767-76. PubMed ID: 15199081
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of oxymorphone extended release in chronic low back pain: results of a randomized, double-blind, placebo- and active-controlled phase III study.
    Hale ME; Dvergsten C; Gimbel J
    J Pain; 2005 Jan; 6(1):21-8. PubMed ID: 15629415
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oxymorphone extended-release tablets relieve moderate to severe pain and improve physical function in osteoarthritis: results of a randomized, double-blind, placebo- and active-controlled phase III trial.
    Matsumoto AK; Babul N; Ahdieh H
    Pain Med; 2005; 6(5):357-66. PubMed ID: 16266356
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oxymorphone and oxymorphone extended release: a pharmacotherapeutic review.
    Sloan PA; Barkin RL
    J Opioid Manag; 2008; 4(3):131-44. PubMed ID: 18717508
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The pain quality response profile of oxymorphone extended release in the treatment of low back pain.
    Gould EM; Jensen MP; Victor TW; Gammaitoni AR; White RE; Galer BS
    Clin J Pain; 2009 Feb; 25(2):116-22. PubMed ID: 19333156
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral extended-release oxymorphone: a new choice for chronic pain relief.
    Matsumoto AK
    Expert Opin Pharmacother; 2007 Jul; 8(10):1515-27. PubMed ID: 17661733
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Six-month, open-label study of hydrocodone extended release formulated with abuse-deterrence technology: Safety, maintenance of analgesia, and abuse potential.
    Hale ME; Ma Y; Malamut R
    J Opioid Manag; 2016; 12(2):139-47. PubMed ID: 27194199
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.